pharma · Pancreatic Adenocarcinoma · Cancer · ACTU
Actuate Therapeutics
ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics is a pharma organization headquartered in Fort Worth, USA. It trades on NYSE under ticker ACTU. Primary therapeutic focus areas include Pancreatic Adenocarcinoma, Cancer, Refractory Hematologic Malig
1751 River Run, Suite 400, Fort Worth, Texas 76107, US HQ
2015 Founded
16 Employees
Public company Type
ACTU · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1751 River Run, Suite 400, Fort Worth, Texas 76107, US
- Founded
- 2015
- Employees
- 16
- Programs
- 12
- Drugs
- 11
- Patents
- 7
9-ING-41
Phase 2 · small molecule · Pancreatic Adenocarcinoma
9-ING-41 for Pancreatic Adenocarcinoma is a Phase 2 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Internal code HCC 22-194
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ACTUATE THERAPEUTICS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Pancreatic Adenocarcinoma
- Status
- terminated
- Trials
- 1